N/A Completed N=28 Treatment

Pharmacist-driven CGM Use in the Uninsured Population

Diabetes

Source: ClinicalTrials.gov NCT03477838 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2021

Primary outcomePrimary: Change in A1c — -0.74 percent of hemoglobin

Summary

This is a pilot study. The purpose is to (1) provide access to continuous glucose monitoring (CGM) to patients (purchased through a grant) and (2) systematically record and analyze the results of the glucose monitoring by the clinical pharmacists at the clinic.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in A1c	-0.74	—
SECONDARY Medication Changes	1.83	—
SECONDARY Glycemic Variability	-3.17; 2.58; 1.5	—

Eligibility Criteria

Inclusion Criteria

adult 18 years of age or older
diagnosis of Type 1 or Type 2 diabetes
A1c greater than 8%
prescribed basal insulin plus either prandial insulin or a glucagon-like peptide-1 (GLP-1) receptor agonist

Exclusion Criteria

pregnant or breast-feeding
on dialysis
not appropriate for CGM use based on clinical judgment by the investigators
patients with limited English proficiency

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03477838). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.